山东大学学报 (医学版) ›› 2024, Vol. 62 ›› Issue (5): 116-120.doi: 10.6040/j.issn.1671-7554.0.2023.0921
张荣雨1,赵文2,李洪欣3,杨闯1,王健2,韩春燕4,李际盛2
中图分类号:
| [1] Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice[J]. Br J Cancer, 2013, 109(7): 1821-1828. [2] 邹琳, 邵伟伟, 李蕾,等. 非小细胞肺癌患者EGFR\ALK\ROS1基因突变状态及其临床意义[J]. 诊断病理学杂志, 2020, 27(2): 85-89. ZOU Lin, SHAO Weiwei, LI Lei, et al. EGFR, ALK and ROS1 gene mutations and their clinical significance in non-small cell lung carcinoma[J]. Chinese Journal of Diagnostic Pathology, 2020, 27(2): 85-89. [3] Russo A, Lopes AR, McCusker MG, et al. New targets in lung cancer(excluding EGFR, ALK, ROS1)[J]. Curr Oncol Rep, 2020, 22(5): 48. doi: 10.1007/s11912-020-00909-8. [4] Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer[J]. Transl Lung Cancer Res, 2015, 4(2): 156-164. [5] Kim M, Jeong JY, Park NJ, et al. Clinical utility of next-generation sequencing in real-world cases: a single-institution study of nine cases[J]. In Vivo, 2022, 36(3): 1397-1407. [6] Pecciarini L, Brunetto E, Grassini G, et al. Gene fusion detection in NSCLC routine clinical practice: targeted-NGS or FISH?[J]. Cells, 2023, 12(8): 1135. doi: 10.3390/cells12081135. [7] Konduri K, Gallant JN, Chae YK, et al. EGFR fusions as novel therapeutic targets in lung cancer[J]. Cancer Discov, 2016, 6(6): 601-611. [8] Di Federico A, Filetti M, Palladini A, et al. EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature[J]. Transl Lung Cancer Res, 2022, 11(3): 497-503. [9] Raez LE, Pinto JA, Schrock AB, et al. EGFR-RAD51 fusion: a targetable partnership originated from the tumor evolution?[J]. J Thorac Oncol, 2018, 13(3): e33-e34. [10] Guan Y, Song Z, Li Y, et al. Effectiveness of EGFR-TKIs in a patient with lung adenocarcinoma harboring an EGFR-RAD51 fusion[J]. Oncologist, 2019, 24(8): 1027-1030. [11] Zhu YC, Wang WX, Xu CW, et al. EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: a case report[J]. Lung Cancer, 2018, 115: 131-134. doi: 10.1016/j.lungcan.2017.12.001. [12] Zhang G, Xia P, Zhao S, et al. Gefitinib combined with cetuximab for the treatment of lung adenocarcinoma harboring the EGFR-intergenic region(SEC61G)fusion and EGFR amplification[J]. Oncologist, 2021, 26(11): e1898-e1902. [13] Copia Sperandio R, Luiza Teixeira Tostes F, Vidal Campregher P, et al. EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: a case report and review of the literature[J]. Lung Cancer, 2022, 166: 94-97. doi: 10.1016/j.lungcan.2022.02.006. [14] Zhong R, Li H, Liu Y, et al. Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: a case report[J]. Thorac Cancer, 2020, 11(2): 456-460. [15] Wang X, Huang L, Cai J, et al. A novel KIF5B-EGFR fusion variant in non-small-cell lung cancer and response to afatinib: a case report[J]. Onco Targets Ther, 2021, 14: 3739-3744. doi: 10.2147/OTT.S313896. [16] Xu H, Shao C. KIF5B-EGFR fusion: a novel EGFR mutation in lung adenocarcinoma[J]. Onco Targets Ther, 2020, 13: 8317-8321. doi: 10.2147/OTT.S263994. [17] Zhu YC, Wang WX, Li XL, et al. Identification of a novel icotinib-sensitive EGFR-SEPTIN14 fusion variant in lung adenocarcinoma by next-generation sequencing[J]. J Thorac Oncol, 2019, 14(8): e181-e183. [18] Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125. [19] Colclough N, Chen K, Johnström P, et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs[J]. Clin Cancer Res, 2021, 27(1): 189-201. [20] Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL study[J]. Eur J Cancer, 2023, 185: 83-93. doi: 10.1016/j.ejca.2023.02.023. |
| [1] | 黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130. |
| [2] | 赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85. |
| [3] | 徐年兴,魏东,乔俊杰,战炳炎. CD8+、IL-6和PaO2对不可切除ⅢB/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35. |
| [4] | 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5. |
| [5] | 刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45. |
| [6] | 李永,崔书君,杨飞,张凡,殷晓霞. 基于增强MRI的亚区域影像组学模型可预测乳腺癌患者新辅助化疗后的病理完全反应[J]. 山东大学学报 (医学版), 2025, 63(1): 81-89. |
| [7] | 韩明勇,于晓黎,曾放平,谢兵,芦兰,瞿家权,江璧锋,唐斯晗,谭洁,梁瑾,钟龙辉,王柳,赵宣植. CT引导经皮肺穿刺肿瘤内化疗技术流程[J]. 山东大学学报 (医学版), 2023, 61(11): 11-19. |
| [8] | 阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30. |
| [9] | 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82. |
| [10] | 陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37. |
| [11] | 马瑞杰,朱良明,左太阳,李春海,张楠,孙志钢. 微波消融治疗非小细胞肺癌根治术后肺寡转移瘤的预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 63-68. |
| [12] | 刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43. |
| [13] | 丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98. |
| [14] | 初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139. |
| [15] | 郭田,付依林,高聆,宋勇峰,付国斌,耿冲,王潍博. 142例女性乳腺癌患者临床特征与甲状腺激素水平的关联分析[J]. 山东大学学报 (医学版), 2020, 58(6): 53-59. |
|
||
